--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-115782" form_type: "8-K" ticker: null cik: "0001270073" company_name: "INTERCEPT PHARMACEUTICALS, INC." filed_at: "2023-11-08T23:59:59+00:00" generated_at: "2026-06-08T08:45:59.111506+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # Alfasigma completes acquisition of Intercept Pharmaceuticals for $19.00 per share ## Summary - Tender offer closed with 74.5% of shares tendered; merger consummated under Section 251(h) without stockholder vote. - Shares delisted from Nasdaq; Company will file Form 15 to suspend SEC reporting obligations. - Board replaced by Alfasigma appointees: Francesco Balestrieri, Stefano Pasi, Michele Cera; Jerome Durso remains CEO, Balestrieri appointed President. - 2.00% Convertible Senior Notes and 3.50% Convertible Senior Secured Notes now convertible into cash at $19.00 per share; holders have repurchase rights. - Certificate of incorporation and bylaws amended and restated as of the merger effective time. ## SEC filing metadata - accession: 0001104659-23-115782 - form_type: 8-K - cik: 0001270073 - company_name: INTERCEPT PHARMACEUTICALS, INC. - filed_at: 2023-11-08T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 1.01, 2.01, 3.01, 2.04, 3.03, 5.01, 5.03, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/tm2330108d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-115782 - JSON: https://secwatch.observer/filing/0001104659-23-115782.json - Plain text: https://secwatch.observer/filing/0001104659-23-115782.txt ## Key facts - Executive change Francesco Balestrieri was appointed as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: appointed - Role: Director source text: The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera. evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Jerome Durso resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Glenn Sblendorio resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Nancy Miller-Rich resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Daniel Bradbury resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Keith Gottesdiener resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Luca Benatti resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Paolo Fundarò resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Mark Pruzanski resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Michele Cera was appointed as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: appointed - Role: Director source text: The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera. evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Gino Santini resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Srinivas Akkaraju resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Francesco Balestrieri was appointed as President at INTERCEPT PHARMACEUTICALS, INC.. - Action: appointed - Role: President source text: Mr. Durso was removed as the President and Mr. Balestrieri was appointed as the President of the Surviving Corporation. evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Jerome Durso was removed as President at INTERCEPT PHARMACEUTICALS, INC.. - Action: removed - Role: President source text: Mr. Durso was removed as the President and Mr. Balestrieri was appointed as the President of the Surviving Corporation. evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Stefano Pasi was appointed as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: appointed - Role: Director source text: The directors of Purchaser immediately prior to the Effective Time were Francesco Balestrieri, Stefano Pasi and Michele Cera. evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Executive change Dagmar Rosa-Bjorkeson resigned as Director at INTERCEPT PHARMACEUTICALS, INC.. - Action: resigned - Role: Director source text: Jerome Durso, Paolo Fundarò, Mark Pruzanski, M.D., Srinivas Akkaraju, M.D., Ph.D., Luca Benatti, Ph.D., Daniel Bradbury, Keith Gottesdiener, M.D., Nancy Miller-Rich, Dagmar Rosa-Bjorkeson, Gino Santini and Glenn Sblendorio each resigned and ceased to be directors evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Governance Changes INTERCEPT PHARMACEUTICALS, INC.: Bylaws amended and restated in their entirety at the Effective Time pursuant to the merger agreement. - Change: bylaw amendment source text: Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in their entirety (the “Second Amended and Restated Bylaws”). evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - Governance Changes INTERCEPT PHARMACEUTICALS, INC.: Certificate of incorporation amended and restated in its entirety at the Effective Time pursuant to the merger agreement. - Change: charter amendment source text: Pursuant to the terms of the Merger Agreement, as of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Amended and Restated Certificate of Incorporation”). evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm - M&A Transactions INTERCEPT PHARMACEUTICALS, INC. underwent a change of control involving Alfasigma S.p.A. for $19.00 per Share in cash (closed 2023-11-08). - Action: change of control - Counterparty: Alfasigma S.p.A. - Consideration: $19.00 per Share in cash - Closing: 2023-11-08 source text: Purchaser commenced a tender offer (the “Offer”) on October 11, 2023, to acquire all of the outstanding shares of the Company’s common stock (the “Shares”) at an offer price of $19.00 per Share, net to the seller in cash, without interest (the “Offer Price”), subject to any applicable withholding taxes. The Offer and related withdrawal rights expired as evidence_url: https://www.sec.gov/Archives/edgar/data/1270073/000110465923115782/0001104659-23-115782-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.